Oncogenic ras genes relate to the development of human cancers. In this study, we used a plasmid-mediated short-hairpin RNA (shRNA) targeting N-ras gene to combine with clinical drug vincristine (VCR) for the treatment of human hepatoma cells. Our results showed that anti-N-Ras shRNA expression vector (pCSH1-shNR) knocked down the target mRNA and protein. Higher efficacy on growth inhibition was observed when pCSH1-shNR was combined with VCR. This synergistic effect was associated with abrogation of VCR-induced overexpressions of P-glycoprotein and multidrug resistance-associated protein 1 by pCSH1-shNR through downregulations of N-Ras and total Ras. Western blot analysis showed that pCSH1-shNR-induced downregulations of N-Ras and total Ras were potentiated by VCR. Following Ras downregulation, phosphorylations of ERK1/2 and Akt were dramatically inhibited by combinatory treatment. The data showed that pCSH1-shNR-induced inhibition of nuclear factor-kB was enhanced by VCR. In addition, the combination of pCSH1-shNR and VCR synergistically inhibited the growth of human hepatoma HepG2 in vivo. Our findings suggested that combination of gene-specific therapeutics and appropriate chemotherapeutic agents might be a promising approach for the treatment of human hepatocellular carcinoma.
Introduction
Although there are surgery, chemotherapy, radiation therapy, percutaneous ethanol injection or liver transplantation, liver cancer is still the third leading cause of cancer death in men and the sixth among women. 1 Hence, the exploration of novel and more effective therapeutic strategies is very crucial. A number of studies have demonstrated that small-interference RNA (siRNA) can inhibit expression of endogenous genes, which supports the notion that oncogene-specific RNA interference (RNAi) may be a new alternative to gene-specific therapeutics of human cancers.
2 Hepatocellular carcinoma (HCC) is the most common primary liver cancer. 3 Specific and powerful gene silencing mediated by RNAi has generated enthusiasm for exploiting for HCC therapy. Some studies demonstrated that silence of HCC-related cellular oncogenes (PTTG, u-PA and VEGF) or the hepatocarcinogenic hepatitis B virus and hepatitis C virus by RNAi effectively inhibited HCC growth in vitro and/or in vivo. Alnylam and Inex Pharmaceuticals have recently advanced a combination systemic drug for the treatment of liver cancer. 3 Although facing challenges, combination of oncogene-specific RNAi and chemotherapy for HCC may be a new therapeutic strategy.
The Ras signaling pathway has attracted considerable attention as a target for anticancer therapy because of its important function in carcinogenesis. Ras proteins are small GTPases that have an important function in a variety of differentiation processes and signal transduction, including the regulation of cell growth, vesicle movement, cell survival, apoptosis and cytoskeleton. 4, 5 Point mutations at specific codons of the normal ras proto-oncogene produce transforming Ras oncogenic proteins that are locked in the active GTP-bound state. 6, 7 Approximately 30% of all human neoplasms harbor a mutation in a ras gene. 8 Ras mediates its effects on cellular proliferation in part by activation of a cascade of kinases: Raf, MEK and ERK1/2. 9 Suppression of oncogenic N-Ras-induced inhibition of mitogen-activated protein kinase (MAPK) activity, cell proliferation and anchorage-independent growth in the human fibrosarcoma HT1080 cell line and the human neuroblastoma SK-N-SH cell line. 10 N-ras mutations are frequently found in HCC. 8 The expression of the N-Ras has previously been shown to be activated to a dominant acting in HCC cell line HepG2.
11 N-Ras may be a promising target for HCC therapy. N-Ras-mediated phosphorylations of ERK1/2 and Akt regulate ERK1/2 and Akt activity, and alterations of ERK1/2 and Akt activity were important facets of the cellular response to microtubule disruption by microtubule inhibitors. [12] [13] [14] The activity of nuclear factorkB (NF-kB) pathway was regulated by Ras and associated with chemosensitivity.
The vinca alkaloid vincristine (VCR) induces cytotoxicity by interacting with and disrupting microtubules, especially those comprising the mitotic spindle apparatus. 15 Although it is conventional clinical medicament for cancer therapy, the neurotoxicity limited its application. 16 In chemotherapy, combination of two or more drugs with different mechanisms is generally available to bring about their synergistic effect and reduce their toxicity. In combination with standard chemotherapy, RNAi therapy can reduce the chemoresistance of certain cancers. 17 In this study, we investigated whether knockdown of N-Ras by plasmid-mediated short-hairpin RNA (shRNA) could inhibit cancer cell proliferation and synergized with VCR to human hepatoma cells. The data displayed that the combination of pCSH1-shNR and VCR had synergistic antitumor activity against HCC in vitro and in vivo. Furthermore, the alterations of intercellular molecules supported this anticancer activity.
Materials and methods

Preparation of shRNA expression vector
The plasmid pCSH1 driven by human H1 promoter was constructed from pSilencer H1 3.0 vector (Ambion Inc., Austin, TX) following the instruction manual. The anti-N-Ras shRNA expression vector pCSH1-shNR transcribed a single-stranded RNA 5 0 -GUGUGAUUUGC CAACAAGGUUCAAGAGACCUUGUUGGCAAAU CACACUUUU-3 0 , which forms stem-loop-structured shRNA, targeting N-Ras mRNA (targeted sequence: 5 0 -GUGUGAUUUGCCAACAAGG-3 0 ). 18 And the nonspecific-target plasmid pCSH1-shMock transcribed a single-stranded RNA 5 0 -GGAUAGUACGAGAUUACA CUUCAAGAGAGUGUAAUCUCGUACUAUCCUUU U-3 0 (targeted sequence: 5 0 -GGAUAGUACGAGAU UACAC-3 0 ). 
Cell culture and transfection
Western blotting
HepG2 cells were washed twice in cold phosphatebuffered saline and then extracted in 100 ml of RIPA lysis buffer (50 mM Tris-HCl (pH 7.5); 1% NP-40; 150 mM NaCl; 1 mg ml À1 aprotinin; 1 mg ml À1 leupeptin; 1 mM Na 3 VO 4 ; 1 mM NaF) at 4 1C for 30 min. Cell debris was removed by centrifugation at 14 000 g for 20 min at 4 1C. Protein concentrations were determined by Bradford assay as described in standard protocol. 19 An amount of 40 mg total protein from whole cell lysate was resolved on 7.5, 10 and 12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). The membranes were blocked with 5% nonfat milk Tris-buffered saline Tween-20 buffer 1 h at room temperature, and incubated for 2 h with primary antibodies. The expression of b-actin was used as loading control. The antibodies were used, including N-Ras, P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), NF-kB, Pin1, Cdk2, cyclin D1, b-actin (Santa Cruz Biotechnology), and total Ras, phospho-ERK1/2, phospho-Akt, IKK-a, IKK-b, IkB-a, phospho-NF-kB, Cdk4, Cdk6 (Cell Signaling Technology, Beverly, MA). The membranes were then incubated for 1 h with horseradish-peroxidase-conjugated goat antimouse, goat anti-rabbit secondary antibody or rabbit anti-goat (Santa Cruz Biotechnology, Santa Cruz, CA). Electrochemiluminescence was carried out according to the manufacturer's instructions with ChemiImager 5500 imaging system (Alpha Innotech Corporation, San Leandro, CA).
Colony formation assay
Cells were seeded at a density of 10 4 in 60-mm tissue culture dishes after cells transfected with 1 mg pCSH1-shMock or 1 mg pCSH1-shNR for 24 h. Cells were fed with new culture medium every 4 days and colonies were counted and measured after 14 days.
SRB assay
Cells were seeded in 24-well plates at a density of 10 4 after cells transfected with 1 mg plasmids for 24 h. After 24 h, cells were cultured with VCR (1.5 or 2.5 nM). Drug concentrations were based on their IC 50 and were adjusted experimentally. After additional incubation of VCR for 72 h, cells were fixed with 50% trichloroacetic acid and SRB (sulforhodamine B) at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out by 1% acetic acid and SRB-bound cells were solubilized with 10 mM Trizma base. The absorbance was read at a wavelength of 492 nm. The percentage of cell survival was calculated.
In vivo tumor model
Female Balb-c nude mice (6-8 weeks old, 22-24 g) were kept under specific pathogen-free conditions. Tumor was raised by subcutaneous injection of 1 Â 10 7 HepG2 cells in 100 ml culture medium without FBS into the right flank. When the tumor nodules (4 Â 4 mm) were established, mice were randomly divided into five groups, and six mice were for each group. From the 5 day after implantation, intratumoral injection of pCSH1-shNR (0.75 mg kg À1 ) was applied every other day for eight times. VCR was administered by i.p. injection at a dose of 0.4 mg kg À1 on day 5. In the combinatory therapy, pCSH1-shNR and VCR were given at the same doses and schedule as above. The control group received physiological saline only. Growth inhibition of transplanted tumors was evaluated by measuring the tumor size every 2 days with the aid of microcalipers. Tumor volume was calculated using the formula ab 2 /2, where a was the length and b the width of the tumor.
Immunohistochemistry
For detection of N-Ras and Ki-67, 5-mm-thick sections were stained with anti-N-Ras polyclonal and anti-Ki-67 monoclonal antibodies (1:100; Santa Cruz Biotechnology). Antigens were visualized using the streptavidinbiotin-peroxidase method. The expressions of N-Ras and Ki-67 for each tumor were the average count of the three most densely stained fields identified using a Â 20 objective. Six different tumors per vehicle control or treatment group were analyzed.
Statistics
Data were described as means±s.d. of the indicated number of separate experiments. A one-way analysis of variance was carried out for multiple comparisons. If there was significant variation between treatment and control groups, the mean values were compared by using Student's t-test. P-values less than 0.05 were considered significant.
Results
Suppression of N-Ras by pCSH1-shNR inhibited HepG2 cell growth
We constructed shRNA transiently expression plasmid pCSH1-shNR targeting N-Ras mRNA and pCSH1-shMock as control. After HepG2 cells were transfected with pCSH1-shMock and pCSH1-shNR, respectively, the inhibitive effect was analyzed by RT-PCR and western blotting. The results showed that pCSH1-shNR effectively inhibited mRNA level and protein expression of N-Ras. In contrast, the expression of N-Ras was not affected by transfection of pCSH1-shMock (Figures 1a and b) .
To examine whether N-Ras suppression affected HepG2 cell growth, we analyzed the effect of pCSH1-shNR Suppression of N-Ras by shRNA-expressing plasmid H-x Sun et al on colony formation. The results showed that pCSH1-shNR markedly inhibited the colony formation and its inhibitory rate was up to 53.9% (Figure 1c ). pCSH1-shMock had less inhibition compared with N-Ras-targeted pCSH1-shNR, indicating that pCSH1-shNR potentiated VCR-induced inhibition of cell growth through special knockdown of N-Ras. (Figure 2b ). These results indicated that the combination of pCSH1-shNR and VCR had remarkable synergistic inhibition of human hepatoma cells growth compared with either alone (Po0.01).
To explore the mechanism of synergistic effect of pCSH1-shNR and VCR, we assessed the protein levels of P-gp and MRP1 by western blotting in HepG2 cells. The results (Figure 2c) showed that VCR alone induced overexpressions of P-gp and MRP1. However, pCSH1-shNR mildly downregulated P-gp and MRP1 expression and attenuated VCR-induced upregulation of P-gp and MRP1, indicating that pCSH1-shNR potentiated VCR cytotoxicity through downregulations of MDR1 and MRP1.
The synergistic effect was regulated by MARP signaling pathway Above data raised a possibility that downregulation of P-gp might be associated with Ras signal pathway. Thus, the activity of proliferation-related Ras/Raf/MEK/ ERK1/2 and Ras/PI3K/Akt signaling pathways were analyzed by western blotting. As shown in Figure 3 
Suppression of N-Ras by shRNA-expressing plasmid
H-x Sun et al pCSH1-shNR markedly inhibited expressions of N-Ras and total Ras and 2.5 nM VCR had less inhibition. However, VCR increased pCSH1-shNR-mediated inhibition of N-Ras and total Ras expressions. In addition, the phosphorylations of ERK1/2 and Akt were analyzed, which represented the activity of the two Ras pathways. Similarly, pCSH1-shNR significantly decreased phosphorylations of ERK1/2 and Akt, and VCR enhanced pCSH1-shNR-mediated dephosphorylations of ERK1/2 and Akt ( Figure 3 ). These data suggested that the combination of pCSH1-shNR and VCR synergistically suppressed the activity of Ras/Raf/MEK/ERK1/2 and Ras/PI3K/Akt signaling pathways and inhibited cancer cell growth.
Combination of pCSH1-shNR and VCR downregulated activation of NF-kB pathway NF-kB is a kind of important nuclear transcription factor. Overexpression and activation of NF-kB are connected with tumorigenesis. 20 Both ERK1/2 and Akt participate in the regulation of NF-kB and activity of NF-kB associates with chemosensitivity to VCR in human multiple myeloma. [21] [22] [23] [24] As shown in Figure 4 , the combination of pCSH1-shNR and VCR downregulated the expression of IKK-a and IKK-b. The expression of IkB-a was mildly upregulated by pCSH1-shNR and downregulated by VCR. The expression and phosphorylation of NF-kB were strongly suppressed by combination of pCSH1-shNR and VCR. We also observed that pCSH1-shNR and the combination significantly decreased the expression of the peptidyl-prolyl cis-trans isomerase Pin1, which protected p65/RelA from ubiquitin-mediated proteolysis. 25 Furthermore, the expressions of cyclin D, Cdk2, Cdk4 and Cdk6 were markedly decreased in pCSH1-shNR-treated cells. VCR enhanced pCSH1-shNR-induced downregulations of cyclin D, Cdk2, Cdk4 and Cdk6 (Figure 4a) . Together, the activation of NF-kB was synergistically downregulated by the combination of pCSH1-shNR and VCR.
In vivo pCSH1-shNR displayed antitumor activity and synergized with VCR to HepG2
The promising results in vitro led us to determine whether N-Ras suppression decreased tumorigenesis and sensitized HepG2 cells to VCR in vivo. Tumor xenografts and treatments were carried out as described in Materials and methods section. The growth rates of tumors treated with VCR, pCSH1-shMock, VCR combined with pCSH1-shMock, pCSH1-shNR and VCR combined with pCSH1-shNR were 74.3, 81.1, 40.5, 51.6 and 3.7%, respectively, on day 30 ( Figure 5 ). These data provide evidence that pCSH1-shNR inhibited oncogenic potential in vivo. Tumors treated with the combination of pCSH1-shNR and VCR showed synergistic reduction compared with other treatments (Po0.05).
The data in vitro indicated that suppression of N-Ras promoted cytotoxicity of VCR and implied that knockdown of N-Ras might enhance inhibition of tumor growth in response to VCR in vivo. In animal model, the effect of the combination on N-Ras expression was evaluated by immunohistochemistry. The expression of Ki-67, which was proliferating cell antigen, was also evaluated. Representative micrographs from xenograft cancer tissues were shown in Figure 6 . Morphometric analysis of the N-Ras immunostaining revealed that the percentage of N-Ras immunoreactivity of control, VCR, pCSH1-shMock, VCR combined with pCSH1-shMock, pCSH1-shNR and VCR combined with pCSH1-shNR were 20.2, 6.1, 23.7, 12.6, 3.8 and 0.8%, respectively ( Figures 6A and B) . In the same way, the percentage of Ki-67 immunoreactivity of control, VCR, pCSH1-shMock, VCR combined with pCSH1-shMock, pCSH1-shNR and VCR combined with pCSH1-shNR were 35.6, 26.7, 31.3, 22.8, 24 .0 and 17.6%, respectively ( Figure 6C ). These data provide evidence that suppression of N-Ras also promoted growth inhibition in response to VCR treatment in vivo. Suppression of N-Ras by shRNA-expressing plasmid H-x Sun et al
Discussion
Our previous data showed that RNA interfering agent hdm2-siRNA silenced its target mRNA specifically and effectively in human breast cancer cells, reduced cell proliferation and induced apoptosis. 26 In addition, hdm2-siRNA significantly synergized with anticancer agent mitomycin to human breast cancer MCF7 cells in xenograft models. In this study, we reported the antihepatoma activity and mechanism of pCSH1-shNR combined with VCR in vitro and in vivo.
Ras proteins normally relay growth-promoting signals from many activated cell-surface receptors. Activating mutations in the Ras proteins result in constitutive signaling, thereby stimulating cell proliferation and inhibiting apoptosis. Oncogenic mutations in the ras gene are present in approximately 30% of all human cancers. 8 N-ras mutations occur frequently in melanoma, hematological malignancy and HCC, 6, 8 which is known to promote tumorigenesis. The ras-signaling pathway has attracted considerable attention as a target for anticancer therapy. 8 We observed that the silencing of N-Ras mRNA resulted directly in decreased colony formation of HepG2 cells with approximately 70% of transfection (data not shown). This result was consistent with that knockout of ras gene in human colon cancer DLD-1 and HCT-116 cells resulted in suppressing expression of the malignant phenotype. 8 In pursuit of better anticancer effect, pCSH1-shNR was combined with VCR. The combination of pCSH1-shNR and VCR had remarkable growth inhibition against liver cancer in vitro and in vivo. This growth inhibition was associated with synergistic downregulation of N-Ras expression induced by the combination of pCSH1-shNR and VCR. Ki-67 is a cellular proliferation marker and overexpression of Ki-67 is associated with poor prognosis in some tumors. 27, 28 Our data showed that expression of Ki-67 in hepatoma HepG2 was dramatically decreased by the combination treatment compared with pCSH1-shNR or VCR alone, indicating that the downregulation of Ki-67 also associated with the synergistic growth inhibition.
The importance of Raf/MEK/ERK kinase cascade in mediating Ras transformation had been demonstrated in NIH3T3 mouse fibroblasts and specific reduction of N-Ras mRNA expression was followed by great inhibition of MAPK activity in human fibrosarcoma HT1080 cells and neuroblastoma SK-N-SH cells. 10, 29 Furthermore, alterations in ERK1/2 activity were important facets of the cellular response to microtubule disruption. It was worthily noticed that VCR inhibited ERK1/2 activity in KB-3 cells. 12 Our data were consistent with these reports that inhibition of N-Ras and treatment of VCR downregulated the phosphorylation of ERK1/2. The dephosphorylation of ERK1/2 was synergistically induced by combination of pCSH1-shNR and VCR ( Figure 3 ). PI3K/Akt pathway was also associated with cell survival, which was regulated by Ras signaling. 30 Akt activity was suppressed by VCR in mammalian cells. 13, 14 Our data demonstrated that phosphorylation of Akt was suppressed by both pCSH1-shNR and VCR, and was markedly downregulated by the combination of them (Figure 3 ). These data suggested that pCSH1-shNR and VCR synergistically suppressed Ras/Raf/MEK/ERK1/2 and Ras/PI3K/Akt signaling pathways, which were associated with inhibition of cell growth.
Experimental studies have shown that downregulation of NF-kB activity by natural and synthetic NF-kB inhibitors suppresses the development of carcinogeninduced tumors, inhibits the growth of cancer cells and induces apoptosis with alternation of gene expression, which is critical for the control of carcinogenesis and cancer cell survival. Moreover, recent studies indicate that the effects of conventional cancer therapeutics could be enhanced by natural and synthetic NF-kB inhibitors, suggesting that downregulation of NF-kB could sensitize cancer cells to conventional therapeutics. 31 In mutant rasexpressing myeloma cells, NF-kB signaling was upregulated. 32 Suppression of oncogenic N-Ras reduced expression of NF-kB in human melanoma cells. 24 Here, our data demonstrated that suppression of N-Ras by pCSH1-shNR interfered with the basal expression of NF-kB (Figure 4) . Moreover, although VCR treatment had no significant effect, the combination of pCSH1-shNR and VCR dramatically downregulated the expression of IKKa and IKK-b, which were members of NF-kB pathway and activated by Ras through ERKs and Akt. [33] [34] [35] IkB-a is an important member of NF-kB pathway. pCSH1-shNR mildly upregulated the expression of IkB-a (Figure 4) , which was in agreement with other previous studies showing that dominant negative mutant of H-Ras prevented the degradation of IkB-a. 36 It has been reported that VCR caused degradation of IkB-a in BCap37 cells, 37 and our data also showed that VCR caused degradation of IkB-a in HepG2 cells. This degradation was probable feedback inhibition in response to VCR-induced downregulation of NF-kB. However, the pretreatment of pCSH1-shNR could partly reverse this degradation and potentiate the downregulation of NF-kB induced by VCR. Furthermore, NF-kB has been implicated in chemoresistance, and downregulation of NF-kB by curcumin-induced chemosensitivity to VCR in human multiple myeloma cells. 23 Similar to curcumin, downregulation of NF-kB by pCSH1-shNR promoted the chemosensitivity to VCR in HepG2 cells. These findings provided further molecular mechanism that the pCSH1-shNR-mediated inhibition of N-Ras promoted VCR efficacy through downregulation of NF-kB.
Constitutive activation of Ras-dependent signaling is important in many tumors, and agents that inhibit this pathway might be useful in numerous therapeutic combinations. Synergistic effect has been documented in human tumor cell lines with mutationally activated Ras treated with MCP110, an inhibitor of Ras-Raf interaction, together with anti-microtubule agents, including paclitaxel, docetaxel and VCR. 38 Drug resistance in human cancer was associated with overexpressions of Pgp and MRP1, and the levels of P-gp and MRP1 were significantly increased in the HepG2/ADM cells compared to the HepG2 cells. 39 VCR could induce the overexpression of P-gp, but not MRP1, in myeloma MGC803 cells. 40 Our data showed that VCR increased the expressions of P-gp and MRP1 in HepG2 cells, and these upregulations were impaired by pCSH1-shNR. It was because that the expression levels of P-gp and MRP1 were regulated by ERKs and Akt, which were inhibited by pCSH1-shNR, 40, 41 and the promoter of human MDR1 gene was shown to be a target for Ras. 42, 43 Moreover, Ras-mediated activation of the MEK/MAP kinase pathway increases cellular levels of cyclin D1, but other effector pathways may also be important in cyclin D1 induction. 8 It has been reported that Ras-mediated activation of the PI3-K pathway leads to G 1 progression. NF-kB also can contribute to cell progression by transcriptionally upregulating cyclin D1, and some cancer cells depend on NF-kB for their survival. 34 We observed that VCR enhanced pCSH1-shNR-induced downregulations of Cdk2, Cdk4 and Cdk6. pCSH1-shNR and the combination also downregulated cyclin D1, which was a downstream molecule of NF-kB, ERK1/2 and Akt pathways. Our results suggested that pCSH1-shNR potentiated the sensitivity of VCR in HepG2 cells was partially contributed by inhibition of cyclin/Cdk system. Importantly, pCSH1-shNR had a measurable antitumor activity in HepG2 xenografted nude mice. Consistent with in vitro data, the most striking result was the drastic reduction in HepG2 tumor volume achieved using the combination of pCSH1-shNR and VCR, indicating a clear synergistic response in vivo. This synergistic effect also was associated with downregulation of N-Ras expression. In summary, our findings strongly imply that Ras signal pathways are excellent targets for liver cancer therapy and combinatorial treatment.
